Based on the key indicators related to ProQR Therapeutics' liquidity, profitability, solvency, and operating efficiency, ProQR Therapeutics BV is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February. At this time, ProQR Therapeutics' Non Current Liabilities Total is relatively stable compared to the past year. As of 01/21/2025, Other Current Assets is likely to grow to about 1.2 M, while Short and Long Term Debt Total is likely to drop slightly above 18.5 M. Key indicators impacting ProQR Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for ProQR Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor ProQR Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in ProQR Therapeutics.
ProQR Therapeutics competes with Annexon, Arrowhead Pharmaceuticals, Day One, Terns Pharmaceuticals, and Alnylam Pharmaceuticals. ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands. Proqr Therapeutics is traded on NASDAQ Exchange in the United States.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what ProQR Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining ProQR Therapeutics's current stock value. Our valuation model uses many indicators to compare ProQR Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ProQR Therapeutics competition to find correlations between indicators driving ProQR Therapeutics's intrinsic value. More Info.
ProQR Therapeutics BV is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, ProQR Therapeutics' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value ProQR Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
ProQR Therapeutics Systematic Risk
ProQR Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. ProQR Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on ProQR Therapeutics correlated with the market. If Beta is less than 0 ProQR Therapeutics generally moves in the opposite direction as compared to the market. If ProQR Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one ProQR Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of ProQR Therapeutics is generally in the same direction as the market. If Beta > 1 ProQR Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in ProQR Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ProQR Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of ProQR Therapeutics growth as a starting point in their analysis.
ProQR Therapeutics January 21, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of ProQR Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of ProQR Therapeutics BV. We use our internally-developed statistical techniques to arrive at the intrinsic value of ProQR Therapeutics BV based on widely used predictive technical indicators. In general, we focus on analyzing ProQR Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ProQR Therapeutics's daily price indicators and compare them against related drivers.
When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.